nodes	percent_of_prediction	percent_of_DWPC	metapath
Orlistat—ABHD12—retina—malignant glioma	0.0153	0.0559	CbGeAlD
Orlistat—DAGLA—central nervous system—malignant glioma	0.0146	0.0531	CbGeAlD
Orlistat—DAGLA—cerebellum—malignant glioma	0.0142	0.0519	CbGeAlD
Orlistat—PLA2G7—medulla oblongata—malignant glioma	0.0126	0.0459	CbGeAlD
Orlistat—FASN—telencephalon—malignant glioma	0.0118	0.0431	CbGeAlD
Orlistat—ABHD16A—medulla oblongata—malignant glioma	0.0118	0.0431	CbGeAlD
Orlistat—DAGLA—brain—malignant glioma	0.0116	0.0421	CbGeAlD
Orlistat—PLA2G7—midbrain—malignant glioma	0.0115	0.042	CbGeAlD
Orlistat—PLA2G7—spinal cord—malignant glioma	0.0112	0.041	CbGeAlD
Orlistat—ABHD12—medulla oblongata—malignant glioma	0.0111	0.0404	CbGeAlD
Orlistat—DAGLB—cerebellum—malignant glioma	0.011	0.0402	CbGeAlD
Orlistat—CYP3A4—Temozolomide—malignant glioma	0.0108	1	CbGbCtD
Orlistat—ABHD16A—midbrain—malignant glioma	0.0108	0.0394	CbGeAlD
Orlistat—ABHD16A—spinal cord—malignant glioma	0.0105	0.0384	CbGeAlD
Orlistat—ABHD12—midbrain—malignant glioma	0.0101	0.0369	CbGeAlD
Orlistat—ABHD12—spinal cord—malignant glioma	0.00988	0.036	CbGeAlD
Orlistat—FASN—medulla oblongata—malignant glioma	0.0093	0.0339	CbGeAlD
Orlistat—DAGLB—brain—malignant glioma	0.00896	0.0327	CbGeAlD
Orlistat—FASN—midbrain—malignant glioma	0.0085	0.031	CbGeAlD
Orlistat—ABHD16A—cerebellum—malignant glioma	0.00836	0.0305	CbGeAlD
Orlistat—FASN—spinal cord—malignant glioma	0.00829	0.0302	CbGeAlD
Orlistat—Faecal incontinence—Carmustine—malignant glioma	0.00791	0.0351	CcSEcCtD
Orlistat—ABHD12—cerebellum—malignant glioma	0.00783	0.0286	CbGeAlD
Orlistat—Faecal incontinence—Temozolomide—malignant glioma	0.00764	0.0339	CcSEcCtD
Orlistat—PLA2G7—brain—malignant glioma	0.00724	0.0264	CbGeAlD
Orlistat—FASN—cerebellum—malignant glioma	0.00657	0.024	CbGeAlD
Orlistat—Haemorrhoids—Temozolomide—malignant glioma	0.00656	0.0291	CcSEcCtD
Orlistat—ABHD12—brain—malignant glioma	0.00636	0.0232	CbGeAlD
Orlistat—Tooth disorder—Temozolomide—malignant glioma	0.00595	0.0264	CcSEcCtD
Orlistat—FASN—brain—malignant glioma	0.00534	0.0195	CbGeAlD
Orlistat—PLA2G4A—medulla oblongata—malignant glioma	0.00447	0.0163	CbGeAlD
Orlistat—Amenorrhoea—Temozolomide—malignant glioma	0.00439	0.0195	CcSEcCtD
Orlistat—Drug interaction—Carmustine—malignant glioma	0.0043	0.0191	CcSEcCtD
Orlistat—PLA2G4A—midbrain—malignant glioma	0.00408	0.0149	CbGeAlD
Orlistat—PLA2G4A—spinal cord—malignant glioma	0.00399	0.0145	CbGeAlD
Orlistat—Vaginal inflammation—Temozolomide—malignant glioma	0.00386	0.0171	CcSEcCtD
Orlistat—Vaginal infection—Temozolomide—malignant glioma	0.00364	0.0161	CcSEcCtD
Orlistat—Neoplasm—Carmustine—malignant glioma	0.00361	0.016	CcSEcCtD
Orlistat—Neoplasm—Temozolomide—malignant glioma	0.00349	0.0155	CcSEcCtD
Orlistat—Diabetes mellitus—Carmustine—malignant glioma	0.00333	0.0148	CcSEcCtD
Orlistat—PLA2G4A—central nervous system—malignant glioma	0.00323	0.0118	CbGeAlD
Orlistat—Hepatic failure—Temozolomide—malignant glioma	0.00312	0.0138	CcSEcCtD
Orlistat—Menopausal symptoms—Temozolomide—malignant glioma	0.00297	0.0132	CcSEcCtD
Orlistat—Thirst—Temozolomide—malignant glioma	0.00294	0.013	CcSEcCtD
Orlistat—Hypokalaemia—Carmustine—malignant glioma	0.00264	0.0117	CcSEcCtD
Orlistat—PLA2G4A—brain—malignant glioma	0.00257	0.00936	CbGeAlD
Orlistat—Dry skin—Temozolomide—malignant glioma	0.00257	0.0114	CcSEcCtD
Orlistat—Hypokalaemia—Temozolomide—malignant glioma	0.00255	0.0113	CcSEcCtD
Orlistat—Breast disorder—Temozolomide—malignant glioma	0.00253	0.0112	CcSEcCtD
Orlistat—Abdominal distension—Temozolomide—malignant glioma	0.00244	0.0108	CcSEcCtD
Orlistat—Sweating increased—Temozolomide—malignant glioma	0.00236	0.0104	CcSEcCtD
Orlistat—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00225	0.00997	CcSEcCtD
Orlistat—Depression—Carmustine—malignant glioma	0.00223	0.00987	CcSEcCtD
Orlistat—Renal failure—Carmustine—malignant glioma	0.00219	0.00973	CcSEcCtD
Orlistat—Neuropathy peripheral—Carmustine—malignant glioma	0.00219	0.0097	CcSEcCtD
Orlistat—Urinary tract infection—Carmustine—malignant glioma	0.00217	0.00962	CcSEcCtD
Orlistat—Infestation—Temozolomide—malignant glioma	0.00216	0.00956	CcSEcCtD
Orlistat—Infestation NOS—Temozolomide—malignant glioma	0.00216	0.00956	CcSEcCtD
Orlistat—Depression—Temozolomide—malignant glioma	0.00215	0.00954	CcSEcCtD
Orlistat—Neuropathy peripheral—Temozolomide—malignant glioma	0.00212	0.00938	CcSEcCtD
Orlistat—Urinary tract infection—Temozolomide—malignant glioma	0.0021	0.0093	CcSEcCtD
Orlistat—Hepatobiliary disease—Temozolomide—malignant glioma	0.00204	0.00905	CcSEcCtD
Orlistat—Sinusitis—Temozolomide—malignant glioma	0.00202	0.00897	CcSEcCtD
Orlistat—Haemoglobin—Carmustine—malignant glioma	0.00201	0.00893	CcSEcCtD
Orlistat—Haemorrhage—Carmustine—malignant glioma	0.002	0.00888	CcSEcCtD
Orlistat—Oedema peripheral—Carmustine—malignant glioma	0.00197	0.00875	CcSEcCtD
Orlistat—Haemoglobin—Temozolomide—malignant glioma	0.00195	0.00863	CcSEcCtD
Orlistat—Haemorrhage—Temozolomide—malignant glioma	0.00194	0.00859	CcSEcCtD
Orlistat—Hepatitis—Temozolomide—malignant glioma	0.00194	0.00859	CcSEcCtD
Orlistat—Pharyngitis—Temozolomide—malignant glioma	0.00192	0.00852	CcSEcCtD
Orlistat—Urinary tract disorder—Temozolomide—malignant glioma	0.00191	0.00848	CcSEcCtD
Orlistat—Oedema peripheral—Temozolomide—malignant glioma	0.00191	0.00846	CcSEcCtD
Orlistat—Urethral disorder—Temozolomide—malignant glioma	0.0019	0.00842	CcSEcCtD
Orlistat—Alopecia—Carmustine—malignant glioma	0.00177	0.00785	CcSEcCtD
Orlistat—Mental disorder—Carmustine—malignant glioma	0.00176	0.00778	CcSEcCtD
Orlistat—Immune system disorder—Temozolomide—malignant glioma	0.00175	0.00776	CcSEcCtD
Orlistat—Mediastinal disorder—Temozolomide—malignant glioma	0.00175	0.00774	CcSEcCtD
Orlistat—Malnutrition—Carmustine—malignant glioma	0.00174	0.00773	CcSEcCtD
Orlistat—Alopecia—Temozolomide—malignant glioma	0.00171	0.00759	CcSEcCtD
Orlistat—Mental disorder—Temozolomide—malignant glioma	0.0017	0.00752	CcSEcCtD
Orlistat—Back pain—Carmustine—malignant glioma	0.00169	0.00748	CcSEcCtD
Orlistat—Malnutrition—Temozolomide—malignant glioma	0.00169	0.00747	CcSEcCtD
Orlistat—Dysgeusia—Temozolomide—malignant glioma	0.00165	0.00732	CcSEcCtD
Orlistat—Vision blurred—Carmustine—malignant glioma	0.00164	0.00729	CcSEcCtD
Orlistat—Back pain—Temozolomide—malignant glioma	0.00163	0.00723	CcSEcCtD
Orlistat—Vision blurred—Temozolomide—malignant glioma	0.00159	0.00704	CcSEcCtD
Orlistat—Ill-defined disorder—Temozolomide—malignant glioma	0.00156	0.00693	CcSEcCtD
Orlistat—Angioedema—Temozolomide—malignant glioma	0.00154	0.00683	CcSEcCtD
Orlistat—Malaise—Temozolomide—malignant glioma	0.00152	0.00674	CcSEcCtD
Orlistat—Vertigo—Temozolomide—malignant glioma	0.00152	0.00672	CcSEcCtD
Orlistat—Convulsion—Carmustine—malignant glioma	0.00151	0.0067	CcSEcCtD
Orlistat—Palpitations—Temozolomide—malignant glioma	0.00149	0.00661	CcSEcCtD
Orlistat—Chest pain—Carmustine—malignant glioma	0.00149	0.00658	CcSEcCtD
Orlistat—Myalgia—Carmustine—malignant glioma	0.00149	0.00658	CcSEcCtD
Orlistat—Anxiety—Carmustine—malignant glioma	0.00148	0.00656	CcSEcCtD
Orlistat—Cough—Temozolomide—malignant glioma	0.00147	0.00652	CcSEcCtD
Orlistat—Convulsion—Temozolomide—malignant glioma	0.00146	0.00648	CcSEcCtD
Orlistat—Myalgia—Temozolomide—malignant glioma	0.00144	0.00636	CcSEcCtD
Orlistat—Anxiety—Temozolomide—malignant glioma	0.00143	0.00634	CcSEcCtD
Orlistat—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00143	0.00632	CcSEcCtD
Orlistat—Oedema—Carmustine—malignant glioma	0.00142	0.00631	CcSEcCtD
Orlistat—Discomfort—Temozolomide—malignant glioma	0.00142	0.00629	CcSEcCtD
Orlistat—Infection—Carmustine—malignant glioma	0.00141	0.00627	CcSEcCtD
Orlistat—Dry mouth—Temozolomide—malignant glioma	0.0014	0.00622	CcSEcCtD
Orlistat—Anaphylactic shock—Temozolomide—malignant glioma	0.00138	0.0061	CcSEcCtD
Orlistat—Oedema—Temozolomide—malignant glioma	0.00138	0.0061	CcSEcCtD
Orlistat—Infection—Temozolomide—malignant glioma	0.00137	0.00606	CcSEcCtD
Orlistat—Nervous system disorder—Temozolomide—malignant glioma	0.00135	0.00598	CcSEcCtD
Orlistat—Skin disorder—Temozolomide—malignant glioma	0.00134	0.00593	CcSEcCtD
Orlistat—Hyperhidrosis—Temozolomide—malignant glioma	0.00133	0.0059	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Carmustine—malignant glioma	0.0013	0.00575	CcSEcCtD
Orlistat—Insomnia—Carmustine—malignant glioma	0.00129	0.00571	CcSEcCtD
Orlistat—Paraesthesia—Carmustine—malignant glioma	0.00128	0.00567	CcSEcCtD
Orlistat—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00125	0.00556	CcSEcCtD
Orlistat—Insomnia—Temozolomide—malignant glioma	0.00124	0.00552	CcSEcCtD
Orlistat—Decreased appetite—Carmustine—malignant glioma	0.00124	0.00549	CcSEcCtD
Orlistat—Paraesthesia—Temozolomide—malignant glioma	0.00124	0.00548	CcSEcCtD
Orlistat—Gastrointestinal disorder—Carmustine—malignant glioma	0.00123	0.00545	CcSEcCtD
Orlistat—Pain—Carmustine—malignant glioma	0.00122	0.0054	CcSEcCtD
Orlistat—Dyspepsia—Temozolomide—malignant glioma	0.00121	0.00537	CcSEcCtD
Orlistat—Decreased appetite—Temozolomide—malignant glioma	0.0012	0.0053	CcSEcCtD
Orlistat—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00119	0.00527	CcSEcCtD
Orlistat—Fatigue—Temozolomide—malignant glioma	0.00119	0.00526	CcSEcCtD
Orlistat—Pain—Temozolomide—malignant glioma	0.00118	0.00522	CcSEcCtD
Orlistat—Feeling abnormal—Carmustine—malignant glioma	0.00117	0.0052	CcSEcCtD
Orlistat—Gastrointestinal pain—Carmustine—malignant glioma	0.00116	0.00516	CcSEcCtD
Orlistat—Feeling abnormal—Temozolomide—malignant glioma	0.00113	0.00503	CcSEcCtD
Orlistat—Abdominal pain—Carmustine—malignant glioma	0.00113	0.00499	CcSEcCtD
Orlistat—Body temperature increased—Carmustine—malignant glioma	0.00113	0.00499	CcSEcCtD
Orlistat—Gastrointestinal pain—Temozolomide—malignant glioma	0.00113	0.00499	CcSEcCtD
Orlistat—Urticaria—Temozolomide—malignant glioma	0.00109	0.00485	CcSEcCtD
Orlistat—Abdominal pain—Temozolomide—malignant glioma	0.00109	0.00482	CcSEcCtD
Orlistat—Body temperature increased—Temozolomide—malignant glioma	0.00109	0.00482	CcSEcCtD
Orlistat—CYP3A4—central nervous system—malignant glioma	0.00107	0.00389	CbGeAlD
Orlistat—Hypersensitivity—Carmustine—malignant glioma	0.00105	0.00465	CcSEcCtD
Orlistat—Asthenia—Carmustine—malignant glioma	0.00102	0.00453	CcSEcCtD
Orlistat—Hypersensitivity—Temozolomide—malignant glioma	0.00101	0.00449	CcSEcCtD
Orlistat—Asthenia—Temozolomide—malignant glioma	0.000987	0.00438	CcSEcCtD
Orlistat—Diarrhoea—Carmustine—malignant glioma	0.000974	0.00432	CcSEcCtD
Orlistat—Pruritus—Temozolomide—malignant glioma	0.000974	0.00432	CcSEcCtD
Orlistat—Dizziness—Carmustine—malignant glioma	0.000942	0.00417	CcSEcCtD
Orlistat—Diarrhoea—Temozolomide—malignant glioma	0.000942	0.00417	CcSEcCtD
Orlistat—Dizziness—Temozolomide—malignant glioma	0.00091	0.00403	CcSEcCtD
Orlistat—Vomiting—Carmustine—malignant glioma	0.000905	0.00401	CcSEcCtD
Orlistat—Rash—Carmustine—malignant glioma	0.000898	0.00398	CcSEcCtD
Orlistat—Dermatitis—Carmustine—malignant glioma	0.000897	0.00398	CcSEcCtD
Orlistat—Headache—Carmustine—malignant glioma	0.000892	0.00395	CcSEcCtD
Orlistat—Vomiting—Temozolomide—malignant glioma	0.000875	0.00388	CcSEcCtD
Orlistat—Rash—Temozolomide—malignant glioma	0.000868	0.00385	CcSEcCtD
Orlistat—Dermatitis—Temozolomide—malignant glioma	0.000867	0.00384	CcSEcCtD
Orlistat—Headache—Temozolomide—malignant glioma	0.000862	0.00382	CcSEcCtD
Orlistat—Nausea—Carmustine—malignant glioma	0.000846	0.00375	CcSEcCtD
Orlistat—Nausea—Temozolomide—malignant glioma	0.000817	0.00362	CcSEcCtD
Orlistat—DAGLA—Signaling by GPCR—PIK3CA—malignant glioma	0.000138	0.000283	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MDM2—malignant glioma	0.000138	0.000282	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MDM2—malignant glioma	0.000138	0.000282	CbGpPWpGaD
Orlistat—FASN—Disease—BRAF—malignant glioma	0.000138	0.000281	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CYP2C18—malignant glioma	0.000138	0.000281	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—RAF1—malignant glioma	0.000137	0.000281	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—RAF1—malignant glioma	0.000137	0.000281	CbGpPWpGaD
Orlistat—PNLIP—Disease—PTEN—malignant glioma	0.000137	0.00028	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—BRAF—malignant glioma	0.000136	0.000278	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—ERBB2—malignant glioma	0.000136	0.000278	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—ERBB2—malignant glioma	0.000136	0.000278	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—FN1—malignant glioma	0.000136	0.000277	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—F2—malignant glioma	0.000136	0.000277	CbGpPWpGaD
Orlistat—FASN—Metabolism—CAV1—malignant glioma	0.000135	0.000275	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CB—malignant glioma	0.000134	0.000274	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CB—malignant glioma	0.000134	0.000274	CbGpPWpGaD
Orlistat—FASN—Disease—AKT2—malignant glioma	0.000134	0.000274	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CB—malignant glioma	0.000133	0.000272	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT2—malignant glioma	0.000133	0.000271	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—BDKRB2—malignant glioma	0.000132	0.000271	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	0.000132	0.00027	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTGS2—malignant glioma	0.000132	0.000269	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CG—malignant glioma	0.00013	0.000265	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	0.00013	0.000265	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CXCL8—malignant glioma	0.000129	0.000263	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CXCL8—malignant glioma	0.000129	0.000263	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CD—malignant glioma	0.000129	0.000263	CbGpPWpGaD
Orlistat—FASN—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	0.000129	0.000263	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—EGF—malignant glioma	0.000128	0.000262	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	0.000128	0.000261	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PTPN11—malignant glioma	0.000128	0.000261	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CD—malignant glioma	0.000127	0.00026	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SUFU—malignant glioma	0.000126	0.000257	CbGpPWpGaD
Orlistat—DAGLB—GPCR downstream signaling—AKT1—malignant glioma	0.000124	0.000254	CbGpPWpGaD
Orlistat—DAGLA—GPCR downstream signaling—AKT1—malignant glioma	0.000124	0.000254	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HEY2—malignant glioma	0.000124	0.000254	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—CASP3—malignant glioma	0.000123	0.000252	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—CASP3—malignant glioma	0.000123	0.000252	CbGpPWpGaD
Orlistat—FASN—Disease—FGF2—malignant glioma	0.000123	0.000252	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—IL2—malignant glioma	0.000123	0.000252	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—IL2—malignant glioma	0.000123	0.000252	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CG—malignant glioma	0.000123	0.000251	CbGpPWpGaD
Orlistat—PNLIP—Disease—STAT3—malignant glioma	0.000123	0.000251	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—FGF2—malignant glioma	0.000122	0.000249	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—GFAP—malignant glioma	0.000121	0.000248	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KNG1—malignant glioma	0.00012	0.000246	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT2—malignant glioma	0.000119	0.000243	CbGpPWpGaD
Orlistat—FASN—Metabolism—PPARG—malignant glioma	0.000118	0.000242	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	0.000118	0.000242	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—malignant glioma	0.000118	0.00024	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPHK1—malignant glioma	0.000117	0.00024	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MMP9—malignant glioma	0.000117	0.000238	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MMP9—malignant glioma	0.000117	0.000238	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PTEN—malignant glioma	0.000116	0.000237	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PTEN—malignant glioma	0.000116	0.000237	CbGpPWpGaD
Orlistat—FASN—Disease—MDM2—malignant glioma	0.000115	0.000236	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HEY1—malignant glioma	0.000115	0.000235	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CCR4—malignant glioma	0.000115	0.000235	CbGpPWpGaD
Orlistat—FASN—Disease—RAF1—malignant glioma	0.000115	0.000235	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PTEN—malignant glioma	0.000115	0.000235	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MDM2—malignant glioma	0.000114	0.000233	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CD—malignant glioma	0.000114	0.000233	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	0.000114	0.000233	CbGpPWpGaD
Orlistat—PNLIP—Disease—MYC—malignant glioma	0.000114	0.000233	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—RAF1—malignant glioma	0.000114	0.000233	CbGpPWpGaD
Orlistat—FASN—Disease—ERBB2—malignant glioma	0.000114	0.000232	CbGpPWpGaD
Orlistat—DAGLA—Signaling by GPCR—AKT1—malignant glioma	0.000113	0.000231	CbGpPWpGaD
Orlistat—DAGLB—Signaling by GPCR—AKT1—malignant glioma	0.000113	0.000231	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—ERBB2—malignant glioma	0.000113	0.00023	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CB—malignant glioma	0.000112	0.000229	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIST1H3B—malignant glioma	0.000112	0.000228	CbGpPWpGaD
Orlistat—PNLIP—Disease—EGFR—malignant glioma	0.000111	0.000228	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTT1—malignant glioma	0.000111	0.000227	CbGpPWpGaD
Orlistat—FASN—Disease—PTGS2—malignant glioma	0.000111	0.000227	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CB—malignant glioma	0.000111	0.000227	CbGpPWpGaD
Orlistat—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	0.000108	0.000221	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CD—malignant glioma	0.000108	0.00022	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—RTEL1—malignant glioma	0.000107	0.000218	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CXCL8—malignant glioma	0.000107	0.000218	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—MMP3—malignant glioma	0.000107	0.000218	CbGpPWpGaD
Orlistat—CYP3A4—Biological oxidations—GSTP1—malignant glioma	0.000106	0.000216	CbGpPWpGaD
Orlistat—PNLIP—Disease—KRAS—malignant glioma	0.000105	0.000215	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—VEGFA—malignant glioma	0.000105	0.000214	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—VEGFA—malignant glioma	0.000105	0.000214	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS1—malignant glioma	0.000104	0.000213	CbGpPWpGaD
Orlistat—CYP3A4—Metapathway biotransformation—GSTP1—malignant glioma	0.000104	0.000213	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	0.000104	0.000212	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—STAT3—malignant glioma	0.000104	0.000212	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—STAT3—malignant glioma	0.000104	0.000212	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—CASP3—malignant glioma	0.000102	0.000209	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JAG2—malignant glioma	0.000102	0.000209	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—IL2—malignant glioma	0.000102	0.000208	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—RAF1—malignant glioma	0.000102	0.000208	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CB—malignant glioma	9.95e-05	0.000203	CbGpPWpGaD
Orlistat—FASN—Disease—PTEN—malignant glioma	9.7e-05	0.000198	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—BCHE—malignant glioma	9.69e-05	0.000198	CbGpPWpGaD
Orlistat—PNLIP—Disease—PIK3CA—malignant glioma	9.67e-05	0.000198	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MMP9—malignant glioma	9.65e-05	0.000197	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—MYC—malignant glioma	9.63e-05	0.000197	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—MYC—malignant glioma	9.63e-05	0.000197	CbGpPWpGaD
Orlistat—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—malignant glioma	9.61e-05	0.000196	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PTEN—malignant glioma	9.6e-05	0.000196	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—SLC5A5—malignant glioma	9.58e-05	0.000196	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—EGFR—malignant glioma	9.42e-05	0.000192	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—EGFR—malignant glioma	9.42e-05	0.000192	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CB—malignant glioma	9.4e-05	0.000192	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTGS2—malignant glioma	9.31e-05	0.00019	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—IL2—malignant glioma	9.14e-05	0.000187	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	9.06e-05	0.000185	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.97e-05	0.000183	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—KRAS—malignant glioma	8.89e-05	0.000182	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—KRAS—malignant glioma	8.89e-05	0.000182	CbGpPWpGaD
Orlistat—FASN—Disease—STAT3—malignant glioma	8.67e-05	0.000177	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—VEGFA—malignant glioma	8.67e-05	0.000177	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—H3F3A—malignant glioma	8.63e-05	0.000176	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—STAT3—malignant glioma	8.58e-05	0.000175	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCR3—malignant glioma	8.55e-05	0.000175	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—YWHAE—malignant glioma	8.32e-05	0.00017	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NTRK2—malignant glioma	8.32e-05	0.00017	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FLT1—malignant glioma	8.28e-05	0.000169	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—DUSP6—malignant glioma	8.25e-05	0.000169	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—PIK3CA—malignant glioma	8.17e-05	0.000167	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—PIK3CA—malignant glioma	8.17e-05	0.000167	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—JAG1—malignant glioma	8.14e-05	0.000166	CbGpPWpGaD
Orlistat—FASN—Metabolism—PTEN—malignant glioma	8.12e-05	0.000166	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH3—malignant glioma	8.11e-05	0.000166	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—PIK3CA—malignant glioma	8.1e-05	0.000166	CbGpPWpGaD
Orlistat—FASN—Disease—MYC—malignant glioma	8.06e-05	0.000165	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—MYC—malignant glioma	7.98e-05	0.000163	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FBXW7—malignant glioma	7.98e-05	0.000163	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—TP53—malignant glioma	7.91e-05	0.000162	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—TP53—malignant glioma	7.91e-05	0.000162	CbGpPWpGaD
Orlistat—PNLIP—Disease—AKT1—malignant glioma	7.9e-05	0.000161	CbGpPWpGaD
Orlistat—FASN—Disease—EGFR—malignant glioma	7.88e-05	0.000161	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.83e-05	0.00016	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BDKRB2—malignant glioma	7.82e-05	0.00016	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—EGFR—malignant glioma	7.8e-05	0.000159	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—F2—malignant glioma	7.79e-05	0.000159	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—VEGFA—malignant glioma	7.76e-05	0.000159	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—GSTP1—malignant glioma	7.71e-05	0.000158	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAT—malignant glioma	7.51e-05	0.000153	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CG—malignant glioma	7.45e-05	0.000152	CbGpPWpGaD
Orlistat—FASN—Disease—KRAS—malignant glioma	7.45e-05	0.000152	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—KRAS—malignant glioma	7.37e-05	0.000151	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PTPN11—malignant glioma	7.32e-05	0.00015	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH2—malignant glioma	7.27e-05	0.000149	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KNG1—malignant glioma	7.12e-05	0.000145	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—NCOR1—malignant glioma	7.09e-05	0.000145	CbGpPWpGaD
Orlistat—FASN—Disease—PIK3CA—malignant glioma	6.84e-05	0.00014	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT2—malignant glioma	6.82e-05	0.000139	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NTRK1—malignant glioma	6.78e-05	0.000139	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—PIK3CA—malignant glioma	6.77e-05	0.000138	CbGpPWpGaD
Orlistat—DAGLB—Signaling Pathways—AKT1—malignant glioma	6.68e-05	0.000136	CbGpPWpGaD
Orlistat—DAGLA—Signaling Pathways—AKT1—malignant glioma	6.68e-05	0.000136	CbGpPWpGaD
Orlistat—PNLIP—Metabolism—AKT1—malignant glioma	6.62e-05	0.000135	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—KRAS—malignant glioma	6.6e-05	0.000135	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—TP53—malignant glioma	6.55e-05	0.000134	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CD—malignant glioma	6.55e-05	0.000134	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP3—malignant glioma	6.3e-05	0.000129	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CDKN2B—malignant glioma	6.25e-05	0.000128	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—COX8A—malignant glioma	6.13e-05	0.000125	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTK2—malignant glioma	6.07e-05	0.000124	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—PIK3CA—malignant glioma	6.06e-05	0.000124	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HES1—malignant glioma	5.96e-05	0.000122	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NCOR1—malignant glioma	5.93e-05	0.000121	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—TP53—malignant glioma	5.87e-05	0.00012	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—RAF1—malignant glioma	5.85e-05	0.00012	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—CAV1—malignant glioma	5.78e-05	0.000118	CbGpPWpGaD
Orlistat—FASN—Metabolism—PIK3CA—malignant glioma	5.73e-05	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CB—malignant glioma	5.71e-05	0.000117	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDGFRA—malignant glioma	5.68e-05	0.000116	CbGpPWpGaD
Orlistat—FASN—Disease—AKT1—malignant glioma	5.59e-05	0.000114	CbGpPWpGaD
Orlistat—PNLIP—Signaling Pathways—AKT1—malignant glioma	5.53e-05	0.000113	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.52e-05	0.000113	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—SPP1—malignant glioma	5.51e-05	0.000113	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—CXCL8—malignant glioma	5.49e-05	0.000112	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CG—malignant glioma	5.26e-05	0.000108	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—IL2—malignant glioma	5.24e-05	0.000107	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TERT—malignant glioma	5.22e-05	0.000107	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—ASMT—malignant glioma	5.22e-05	0.000107	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PDGFB—malignant glioma	5.1e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PPARG—malignant glioma	5.08e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGFR1—malignant glioma	5.07e-05	0.000104	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—HIF1A—malignant glioma	5e-05	0.000102	CbGpPWpGaD
Orlistat—PLA2G4A—Hemostasis—AKT1—malignant glioma	4.95e-05	0.000101	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BCAN—malignant glioma	4.9e-05	0.0001	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CAV1—malignant glioma	4.83e-05	9.88e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KDR—malignant glioma	4.78e-05	9.77e-05	CbGpPWpGaD
Orlistat—FASN—Metabolism—AKT1—malignant glioma	4.68e-05	9.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CD—malignant glioma	4.63e-05	9.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FN1—malignant glioma	4.6e-05	9.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—F2—malignant glioma	4.6e-05	9.4e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BAD—malignant glioma	4.54e-05	9.29e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—NOTCH1—malignant glioma	4.5e-05	9.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CD80—malignant glioma	4.41e-05	9.01e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—APC—malignant glioma	4.4e-05	9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CG—malignant glioma	4.4e-05	9e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGF—malignant glioma	4.35e-05	8.89e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTPN11—malignant glioma	4.32e-05	8.84e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—BRAF—malignant glioma	4.14e-05	8.46e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CB—malignant glioma	4.03e-05	8.24e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT2—malignant glioma	4.03e-05	8.23e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—EGFR—malignant glioma	4.01e-05	8.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTGS2—malignant glioma	4e-05	8.17e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—IDH2—malignant glioma	3.95e-05	8.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CD—malignant glioma	3.87e-05	7.91e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—KRAS—malignant glioma	3.79e-05	7.74e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2B6—malignant glioma	3.72e-05	7.6e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—FGF2—malignant glioma	3.7e-05	7.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PTEN—malignant glioma	3.49e-05	7.12e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—PIK3CA—malignant glioma	3.48e-05	7.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MDM2—malignant glioma	3.47e-05	7.08e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—RAF1—malignant glioma	3.45e-05	7.06e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—ERBB2—malignant glioma	3.42e-05	6.98e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—IDH1—malignant glioma	3.4e-05	6.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CB—malignant glioma	3.37e-05	6.89e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SPHK1—malignant glioma	3.29e-05	6.72e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CXCL8—malignant glioma	3.24e-05	6.62e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CYP2C18—malignant glioma	3.22e-05	6.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—CASP3—malignant glioma	3.1e-05	6.34e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—IL2—malignant glioma	3.1e-05	6.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MMP9—malignant glioma	2.93e-05	5.99e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PTEN—malignant glioma	2.91e-05	5.96e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling by GPCR—AKT1—malignant glioma	2.84e-05	5.81e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—VEGFA—malignant glioma	2.63e-05	5.38e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTT1—malignant glioma	2.61e-05	5.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—STAT3—malignant glioma	2.61e-05	5.33e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—PIK3CA—malignant glioma	2.46e-05	5.03e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS1—malignant glioma	2.44e-05	4.99e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—MYC—malignant glioma	2.42e-05	4.95e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—EGFR—malignant glioma	2.37e-05	4.84e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—BCHE—malignant glioma	2.27e-05	4.64e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—SLC5A5—malignant glioma	2.24e-05	4.58e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—KRAS—malignant glioma	2.24e-05	4.57e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—PIK3CA—malignant glioma	2.06e-05	4.2e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Metabolism—AKT1—malignant glioma	2.01e-05	4.11e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—TP53—malignant glioma	1.99e-05	4.06e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—GSTP1—malignant glioma	1.81e-05	3.69e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAT—malignant glioma	1.76e-05	3.59e-05	CbGpPWpGaD
Orlistat—PLA2G4A—Signaling Pathways—AKT1—malignant glioma	1.68e-05	3.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—NCOR1—malignant glioma	1.66e-05	3.39e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—CAV1—malignant glioma	1.35e-05	2.77e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.23e-05	2.52e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PPARG—malignant glioma	1.19e-05	2.43e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.08e-05	2.21e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CB—malignant glioma	9.45e-06	1.93e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTGS2—malignant glioma	9.36e-06	1.91e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PTEN—malignant glioma	8.16e-06	1.67e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—PIK3CA—malignant glioma	5.76e-06	1.18e-05	CbGpPWpGaD
Orlistat—CYP3A4—Metabolism—AKT1—malignant glioma	4.7e-06	9.61e-06	CbGpPWpGaD
